

GenBio Announces Radical Breakthrough in First Phase of Research

The manufacturing process was novel in removing the inherent oils, thus concentrating the antioxidant polyphenol classes of bioactive compounds.

ALISO VIEJO, CA, UNITED STATES,
August 17, 2022 /EINPresswire.com/ --
GenBio Inc. has just completed its first phase research into a more refined indigenous Australian extract, the first of its kind. The manufacturing process was novel in removing the inherent

oils, thus concentrating the antioxidant polyphenol classes of bioactive compounds. It is envisaged that this extract with potentially increased potency will remain in the herbal/dietary classification of food grade products, enabling entirely new ranges of nutraceutical products to be designed for even more effective immune support and improved overall human health. The

“ unique extract is now undergoing further specialized high resolution chromatographic and biochemical research to define the individual compounds and their specific mechanisms of action for health support.

Let food be thy medicine
and medicine be thy food.”

Hippocrates

Emphasis will be placed on those mechanisms that will

improve the handling of dietary fats in the body, especially normalizing the diet-induced changes in the gut microbiome, improving the handling of fats by the liver, and reversing changes in fat transport in the blood. This multi-pronged attack will allow lower doses of the extract to reduce the symptoms of chronic human disease.

About GenBio, Inc.

GenBio, Inc. (<https://genbioinc.com/>) aims to create, through its IND Drug program, the next generation of anti-inflammatory drugs with the intention to disrupt the projected \$191 billion+ anti-inflammatory drug market. GenBio, in addition, has access to a vast catalog of natural herbs, extracts, superfoods and functional food ingredients that can and will be formulated and licensed out to create a range of new nutraceuticals to aid in boosting the human immune system and promoting good health and longevity.



Forward Looking Statements

Statements in this press release about the future expectations, including without limitation, the likelihood that GenBio, Inc. will be able to meet minimum expectations, be successful and leverage capital markets to execute its growth strategy, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unexpected events, except as required by law. GenBio's business strategy described in this press release is subject to innumerable risks, most significantly, whether the Company is successful in securing adequate financing. No information in this press release should be construed in any form, shape, or manner as an indication of the Company's future revenues or financial condition.

Contact:

Todd D. Sonoga

GenBio Inc.

+1 949-705-8021

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/586385114>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.